These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25209519)

  • 21. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents.
    Wilhelm KP; Wilhelm D; Neumeister C; Zsolt I; Schwantes U
    Clin Exp Dermatol; 2012 Mar; 37(2):112-7. PubMed ID: 22103435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
    Tato M; López Y; Morosini MI; Moreno-Bofarull A; Garcia-Alonso F; Gargallo-Viola D; Vila J; Cantón R
    Diagn Microbiol Infect Dis; 2014 Mar; 78(3):263-7. PubMed ID: 24321353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ozenoxacin Cream, 1% - Topical Treatment of Impetigo.
    Gupta AK; Versteeg SG; Abramovits W
    Skinmed; 2017; 15(1):57-59. PubMed ID: 28270312
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
    Mallikaarjun S; Salazar DE; Bramer SL
    J Clin Pharmacol; 2004 Feb; 44(2):179-87. PubMed ID: 14747427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers.
    Kecskés A; Jahn P; Wendt H; Kleine-Kuhlmann R; Lange L
    Arzneimittelforschung; 1993 Feb; 43(2):144-7. PubMed ID: 8457237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations.
    Levinson RS; Mitan SJ; Steinmetz JI; Gattermeir DJ; Schumacher RJ; Joffrion JL
    Clin Ther; 2005 Dec; 27(12):1894-900. PubMed ID: 16507375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo.
    Hebert AA; Rosen T; Albareda López N; Zsolt I; Masramon X
    Int J Womens Dermatol; 2020 Mar; 6(2):109-115. PubMed ID: 32258344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
    Walters T; Rinehart M; Krebs W; Holdbrook M
    Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local tolerability and effectiveness of Ketospray® 10% cutaneous spray solution.
    Fulga I; Lupescu O; Spircu T
    Panminerva Med; 2012 Dec; 54(1 Suppl 4):23-33. PubMed ID: 23241932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.
    Still JG; Clark K; Degenhardt TP; Scott D; Fernandes P; Gutierrez MJ
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S504-12. PubMed ID: 21546627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
    Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
    Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.